Pediatric allergic rhinitis and asthma: Can the march be halted?

O.A. Tsilochristou; N. Douladiris; M. Makris; N.G. Papadopoulos

doi:10.1007/s40272-013-0043-3

Pediatric allergic rhinitis and asthma: Can the march be halted?

O.A. Tsilochristou, N. Douladiris, M. Makris, N.G. Papadopoulos

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of ‘united airways disease’ or ‘respiratory allergy’, implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the ‘atopic march’. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

Original language	English
Pages (from-to)	431-440
Number of pages	10
Journal	Pediatric Drugs
Volume	15
Issue number	6
DOIs	https://doi.org/10.1007/s40272-013-0043-3
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40272-013-0043-3

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890491762&doi=10.1007%2fs40272-013-0043-3&partnerID=40&md5=c7dfca9640adbd8c3a1d5539e7ef7476

Cite this

@article{2f0fbbd7d18e4458b67a5cac35146196,

title = "Pediatric allergic rhinitis and asthma: Can the march be halted?",

abstract = "The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of {\textquoteleft}united airways disease{\textquoteright} or {\textquoteleft}respiratory allergy{\textquoteright}, implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the {\textquoteleft}atopic march{\textquoteright}. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.",

author = "O.A. Tsilochristou and N. Douladiris and M. Makris and N.G. Papadopoulos",

year = "2013",

doi = "10.1007/s40272-013-0043-3",

language = "English",

volume = "15",

pages = "431--440",

journal = "Pediatric Drugs",

number = "6",

}

TY - JOUR

T1 - Pediatric allergic rhinitis and asthma

T2 - Can the march be halted?

AU - Tsilochristou, O.A.

AU - Douladiris, N.

AU - Makris, M.

AU - Papadopoulos, N.G.

PY - 2013

Y1 - 2013

N2 - The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of ‘united airways disease’ or ‘respiratory allergy’, implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the ‘atopic march’. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

AB - The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of ‘united airways disease’ or ‘respiratory allergy’, implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the ‘atopic march’. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

U2 - 10.1007/s40272-013-0043-3

DO - 10.1007/s40272-013-0043-3

M3 - Article

VL - 15

SP - 431

EP - 440

JO - Pediatric Drugs

JF - Pediatric Drugs

IS - 6

ER -

Pediatric allergic rhinitis and asthma: Can the march be halted?

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this